Angelini Ventures has invested €11.5 million in Dutch biotech company Laigo Bio to advance its pioneering solutions in targeted protein degradation for oncology and autoimmune diseases.

Target Company Overview

Laigo Bio is a pioneering Dutch biotechnology firm focused on the development of innovative solutions for selective protein degradation, particularly in the fields of oncology and autoimmune diseases. The company is leading the charge in addressing significant challenges in these critical areas of healthcare, making strides towards advancing therapeutic options that could significantly benefit patients.

With its groundbreaking approach, Laigo Bio aims to develop first-in-class treatments that can effectively target and degrade specific membrane-bound proteins implicated in cancer and autoimmune disorders. The company’s vision is driven by a commitment to transforming the landscape of protein degradation therapies.

Industry Overview in the Netherlands

The biotechnology sector in the Netherlands is characterized by its robust growth, supported by a highly skilled workforce and a collaborative research environment.